AlphaMadera's AlphaVal page computes Arcutis Biotherapeutics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ARQT as undervalued, fairly valued, or overvalued.

What is Arcutis Biotherapeutics, Inc.'s fair value?

Fair value for ARQT is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ARQT?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ARQT's most recent reported fundamentals.

ARQT - Arcutis Biotherapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $35.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: ARQT has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.